An optofluidic system for the concentration gradient screening of oocyte protection drugs

Dongyong Yang1, Qinghao Hu2, Shukun Zhao2

  • 1Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.

Talanta
|June 26, 2024
PubMed

Insights

A novel optofluidic system enables efficient in vitro oocyte drug screening. Melatonin protects oocytes from fluorene-9-bisphenol (BHPF) damage, offering potential for reproductive health research.

Area of Science:

  • Reproductive Biology
  • Biomedical Engineering
  • Toxicology

Background:

  • Oocyte drug screening is crucial for reproductive disease treatment.
  • Existing microfluidic systems face challenges due to oocyte size, scarcity, and environmental sensitivity.
  • Developing advanced in vitro screening platforms is essential.

Purpose of the Study:

  • To develop an optofluidic system for oocyte drug screening and state analysis.
  • To assess the protective effects of melatonin against fluorene-9-bisphenol (BHPF) induced oocyte damage.
  • To demonstrate the system's utility for multi-concentration drug screening.

Main Methods:

  • Construction of an open-top microfluidic chip for single oocyte culture with hydrogel anchoring.
  • Integration of an optical Fourier filter analysis component for oocyte status assessment.
  • In vitro drug screening assay using fluorene-9-bisphenol (BHPF) and melatonin.

Main Results:

  • The optofluidic system successfully cultured and analyzed single oocytes.
  • Fluorene-9-bisphenol (BHPF) was found to damage the oocyte spindle in a dose-dependent manner.
  • A high dose of melatonin (10⁻³ M) significantly reduced abnormal chromosome arrangements in BHPF-exposed oocytes.

Conclusions:

  • The developed optofluidic system is promising for oocyte culture and drug screening.
  • This technology facilitates convenient, multi-concentration screening of oocyte protective drugs.
  • The system holds potential for future applications in biomedicine and reproductive toxicology.